Fundraising FoxSV Health Investors — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundLongwood FundRidgeback Capital+4 more
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)inEric Morgen(Founder)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesLongitude Capital+19 more
SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.
AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US
Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in
Board seatPaul LaViolette· per SEC Form D
Co-investorsLumira VenturesS3 VenturesDeerfield Management CompanyJohnson & Johnson Innovation – JJDC
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)inKevin Pojasekin
Co-investorsRA CapitalSamsara BioCapitalPfizer VenturesDementia Discovery FundM VenturesPfizer Venture Investments
Spineology develops minimally invasive spine surgery implants, including its flagship OptiMesh interbody fusion technology that delivers a bone graft-containing implant through a small surgical portal.
BiotechHardwareHealthtechMedical DevicesSt. Paul, US
Stephen D. Kuslich(Founder)JAMISON YOUNG(Executive Officer)inBrian Snider(Chief Executive Officer & Board Member)inSteve Nemitz(Chief Financial Officer)inAmanda Bloom(Executive Vice President, Marketing)inEmory Rooney(Executive Vice President, Sales)in
Co-investors1315 CapitalGroundswell VenturesRC Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.